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“Optimized Antiplatelet Therapy”
Based on Ethnicity
We read with interest the CILON-T (Influence of Cilostazol-
based Triple Antiplatelet Therapy on Ischemic Complication
After Drug-Eluting Stent Implantation) trial on the efficacy of
cilostazol on ischemic complications after drug-eluting stent
(DES) implantation (1), which suggested the potential link be-
tween platelet reactivity and ischemic events in Asians.
Asians exhibit poor response to clopidogrel, maybe due to the
high prevalence of CYP2C19*2/*3 allele carriage (55% to 70%)
(1). In the CILON-T study, 50% of the patients receiving dual
antiplatelet therapy had high platelet reactivity based on Western
population (P2Y12 reaction units [PRU] 235). However, similar
to other Asian studies, the CILON-T study showed a low
ischemic events rate (2% during 6 months). In the CILON-T
study, patients under the certain PRU (210) were absent from
ischemic events (1). Meanwhile, the GRAVITAS trial demon-
strated a different threshold (175 PRU), showing the complete
immunity against 6-month thrombotic events in DES-treated
patients (2). Accordingly, we may hypothesize that Asians have
different thresholds for efficacy and safety compared to Western
populations.
Moreover, despite similar prevalence of CYP2C19*2/*3 variants
between East and South Asians, 1-week double-dose versus
standard-dose clopidogrel in acute coronary syndrome patients
showed the different ischemic events rate (3). Hypercoagulable
states are also associated with coagulation and fibrinolytic systems,
and inflammation, which are affected by environmental and
genetic factors. Differences in these components may explain
interracial disparity in the occurrence of atherothrombosis.
In the CILON-T study, platelet measures were performed 1 to
3 days after cilostazol loading. Investigators did not mention the
time interval between sampling and oral administration. Because
cilostazol reversibly inhibits platelets, its response can be more time
dependent, and the maximal effect appears later. Additionally, if a
whole blood assay (e.g., VerifyNow [Accumetrics, San Diego,
California]) is used, ex-vivo measurement can underestimate the
actual in-vivo effect of cilostazol because the red cells rapidly take
up plasma adenosine (4). Six-month clinical follow-up may be too
short to evaluate post-DES pleiotrophic effects of cilostazol.
Taken together, the CILON-T study may not be considered as
a conclusive trial, but as a starting point for new, interesting ideas.
Future trials need to include diverse ethnicity and convincing
experiments to reflect in-vivo effects of the study drug. It is hoped
that these novel concepts will assist in developing an “optimized
antiplatelet therapy.”
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Reply
We cordially appreciate the interest of Dr. Jeong and colleagues in
our paper (1) and welcome their comments. The CILON-T
(Influence of Cilostazol-based Triple Antiplatelet Therapy on
Ischemic Complication After Drug-Eluting Stent Implantation)
trial was designed to compare the efficacy and safety of dual and
triple antiplatelet therapy in patients undergoing percutaneous
coronary intervention in the real-world setting (1). It showed that
the individual response to antiplatelet therapy rather than the
choice of specific regimen is important to predict future adverse
events, and it suggested the cut-off P2Y12 reaction unit (PRU)
alues in Asians, which has not been well reported.
We took comments well regarding limitations of CILON-T
rial. Cilostazol reversibly inhibits platelets, and its response can be
ore time dependent. Previous reports showed that inhibition of
denosine-diphosphate–induced platelet aggregation was signifi-
antly higher in patients receiving triple therapy than in patients
eceiving dual therapy at 24 h (2). In addition, we could find
imilar antiplatelet action of triple antiplatelet therapy at discharge
nd at 6 months. Therefore, we do not think that our sampling
iming was too early to observe the action of cilostazol.
We completely agree with Dr. Jeong and colleagues that Asians
ay have different thresholds for efficacy and safety to antiplatelet
herapy compared with the Western population. It may be partially
xplained by a high prevalence of CYP2C19*2/*3 variants. How-
ver, there seems to be discrepancy between the prevalence of high
ost-treatment platelet reactivity (PPR) and clinical events in
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July 5, 2011:196–201Asians. It may suggest that PPR would be 1 of numerous risk
factors of atherothrombosis and that the role of it may not explain
the whole clinical events after percutaneous coronary intervention.
Previous studies reported that high PPR is associated with poor
clinical outcomes in patients with coronary artery disease (3,4).
owever, it is not clear that tailored dosing or choice of antiplate-
et agents based on platelet function test can improve the prognosis
f patients with high PPR. The GRAVITAS (Gauging Respon-
iveness With A VerifyNow Assay–Impact on Thrombosis and
afety) trial could not show the benefit of high-dose clopidogrel
herapy in patients with high PPR (5). The TRIGGER-PCI
Testing Platelet Reactivity in Patients Undergoing Elective Stent
lacement on Clopidogrel to Guide Alternative Therapy With
rasugrel) study was stopped early after an interim analysis
evealed a primary event rate too low to allow for any meaningful
omparison between clopidogrel and prasugrel (6). The results of
major trials make us question whether PPR would be a
odifiable factor of thrombosis or simply an intrinsic property
eflecting one’s thrombotic status. Further studies are warranted to
nvestigate these unsolved problems, especially regarding the eth-
ic difference of response to antiplatelet regimen and the necessi-
ies of personalized antiplatelet therapies.
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2011.Vasovagal Syncope as a Cause of
Syncope in Long-QT Syndrome
The report by Liu et al. (1) containing data from the International
ong QT Syndrome Registry regarding the risk factors for
ecurrent syncope and subsequent fatal or near fatal events in
hildren and adolescents with long-QT syndrome (LQTS) who
resent for evaluation after episodes of syncope is of great interest.
he registry includes all sorts of syncopal episodes, and in their
iscussion, Liu et al. aptly emphasize that risk stratification in
hese patients requires careful examination to distinguish whether
syncopal episode stemmed from LQTS-associated dysrhythmia
r whether it was simply a vasovagally mediated episode occurring
n an LQTS host.
In the general population, a vasovagal faint is by far the most
requent cause of syncope (2). It refers to a syncopal episode
nduced by a fall in blood pressure and cerebral hypoperfusion due
o reflex response upon various triggering factors (standing up,
rolonged orthostatic stress, reaction to blood taking, and so on).
he underlying mechanism is a loss of vasoconstrictor tone
ssociated with relative or absolute bradycardia. Although some
atients present with clear and prolonged premonitory symptoms,
cute onset has also been reported (3). In general, the overall
rognosis in patients with vasovagal syncope is excellent (4).
The lifetime cumulative incidence of 1 syncopal episode in
eenagers in the general population is high, with about 40% by age
1 years (2,5). This is almost identical to the cumulative prevalence
f 41% in children and adolescents with prolonged corrected QT
ntervals or young carriers of LQTS-causing mutations in the
tudy by Liu et al. (1). There is no reason to assume that vasovagal
yncope has a lower prevalence in patients with LQTS than in the
eneral population. Thus, whereas syncope in the setting of LQTS
s definitively a red flag, given the risk for fatal arrhythmic events
6), the epidemiological data on the frequency of vasovagal syncope
n the general population suggest that the vast majority of syncopal
pisodes in patients with LQTS are caused by vasovagal syncope.
he obvious challenge for clinicians is to identify the patients who
re at risk. With an additional positive family history of syncope or
udden death (3), the identification of high-risk patients would
possibly be more accurate.
Thus, although the risk for an aborted cardiac arrest or
LQTS-related sudden cardiac death rises with the occurrence of
syncopal episodes, syncope does not equate to torsades de pointes,
especially not in the young, and careful history taking remains a
cornerstone of diagnosis and treatment in these patients.
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